# O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait

> **NCT05716724** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 288 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT05716724
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-25
- **Primary completion:** 2023-07-09
- **Final completion:** 2023-07-09
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05716724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05716724, "O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05716724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*